Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp.

TNXP | NASDAQ
Chart Builder DCF Calculator
$10.95
+$0.23 (+2.15%)
Sep 22, 2026, 11:15 AM ET · Market open

Company Profile

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.

Key Executives

Name Position
Seth Lederman Co-Founder, Interim Chief Medical Officer, President, CEO & Chairman
Bradley Saenger Chief Financial Officer & Treasurer
Jessica Edgar Morris Chief Operating Officer
Darryl Rideout Executive Vice President of Experimental Chemistry
Ganesh Kamath Head of Market Access
Gregory Sullivan Secretary
Irina Ishak General Counsel
Sina Bavari Executive Vice President of Infectious Disease Research & Development
Siobhan Fogarty Chief Technical Officer
Thomas Englese Executive Vice President of Commercial Operations
Zeil Rosenberg Executive Vice President of Medical

Latest SEC Filings

Date Type Title
Aug 31, 2026 4 Filing
Aug 24, 2026 4 Filing
Aug 18, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 10, 2026 10-Q Quarterly Report
Aug 10, 2026 8-K Current Report
Aug 03, 2026 8-K Current Report
Jul 21, 2026 8-K Current Report
Jul 13, 2026 8-K Current Report
View All SEC Filings
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. logo
Country United States
IPO Date May 9, 2012
Industry Biotechnology
Sector Healthcare
Employees 142
CEO Seth Lederman

Contact Details

200 Connell Drive Berkeley Heights, New Jersey 07928 United States

Stock Details

Ticker Symbol TNXP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001430306
CUSIP Number 890260839
ISIN Number US8902608392
SIC Code 2834

© 2026 bestshares.com. All rights reserved.